Published in J Bone Miner Res on May 01, 2012
Relationships between inflammation, immune activation, and bone health among HIV-infected adults on stable antiretroviral therapy. J Acquir Immune Defic Syndr (2014) 0.99
C-reactive protein, bone strength, and nine-year fracture risk: data from the Study of Women's Health Across the Nation (SWAN). J Bone Miner Res (2013) 0.98
Inflammatory markers and risk of hip fracture in older white women: the study of osteoporotic fractures. J Bone Miner Res (2014) 0.95
C-reactive protein, bone loss, fracture, and mortality in elderly women: a longitudinal study in the OPRA cohort. Osteoporos Int (2014) 0.82
Association between inflammatory biomarkers and bone mineral density in a community-based cohort of men and women. Arthritis Care Res (Hoboken) (2014) 0.82
Obstructive sleep apnea and metabolic bone disease: insights into the relationship between bone and sleep. J Bone Miner Res (2015) 0.82
Hypoxia during sleep and the risk of falls and fractures in older men: the Osteoporotic Fractures in Men Sleep Study. J Am Geriatr Soc (2014) 0.81
OPG and sRANKL serum levels and incident hip fracture in postmenopausal Caucasian women in the Women's Health Initiative Observational Study. Bone (2013) 0.79
Pro-inflammatory cytokines and bone fractures in CKD patients. An exploratory single centre study. BMC Nephrol (2012) 0.79
TNF Receptors Predict Hip Fracture Risk in the WHI Study and Fatty Acid Intake Does Not Modify This Association. J Clin Endocrinol Metab (2015) 0.78
Inflammatory Markers and the Risk of Hip and Vertebral Fractures in Men: the Osteoporotic Fractures in Men (MrOS). J Bone Miner Res (2016) 0.78
Interferon gamma (IFN-γ)-mediated inflammation and the kynurenine pathway in relation to risk of hip fractures: the Hordaland Health Study. Osteoporos Int (2014) 0.77
Associations of total and free 25OHD and 1,25(OH)2D with serum markers of inflammation in older men. Osteoporos Int (2016) 0.76
Dietary Inflammatory Index, Bone Mineral Density and Risk of Fracture in Postmenopausal Women: Results from the Women's Health Initiative. J Bone Miner Res (2016) 0.75
Soluble CD14 and fracture risk. Osteoporos Int (2015) 0.75
Triglyceride Levels and Fracture Risk in Midlife Women: Study of Women's Health Across the Nation (SWAN). J Clin Endocrinol Metab (2016) 0.75
Association of blood neutrophil lymphocyte ratio in the patients with postmenopausal osteoporosis. Pak J Med Sci (2016) 0.75
IL-6 Contributes to the Defective Osteogenesis of Bone Marrow Stromal Cells from the Vertebral Body of the Glucocorticoid-Induced Osteoporotic Mouse. PLoS One (2016) 0.75
Conjugated linoleic Acid prevents ovariectomy-induced bone loss in mice by modulating both osteoclastogenesis and osteoblastogenesis. Lipids (2013) 0.75
Inflammatory Markers and Frailty in Long-Term Care Residents. J Am Geriatr Soc (2017) 0.75
A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab (1999) 10.64
Measurement characteristics of the Women's Health Initiative food frequency questionnaire. Ann Epidemiol (1999) 10.36
The RAND 36-Item Health Survey 1.0. Health Econ (1993) 10.05
Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet (1993) 9.34
Outcomes ascertainment and adjudication methods in the Women's Health Initiative. Ann Epidemiol (2003) 8.64
The Women's Health Initiative recruitment methods and results. Ann Epidemiol (2003) 8.42
Walking compared with vigorous exercise for the prevention of cardiovascular events in women. N Engl J Med (2002) 7.77
Implementation of the Women's Health Initiative study design. Ann Epidemiol (2003) 7.30
Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med (1999) 6.92
Frailty: emergence and consequences in women aged 65 and older in the Women's Health Initiative Observational Study. J Am Geriatr Soc (2005) 6.73
Calculation of free and bound fractions of testosterone and estradiol-17 beta to human plasma proteins at body temperature. J Steroid Biochem (1982) 5.98
Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med (2004) 5.86
Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature (1986) 5.68
Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science (1992) 5.18
Serum IL-6 level and the development of disability in older persons. J Am Geriatr Soc (1999) 4.84
Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes (2004) 4.67
Undertreatment of osteoporosis in men with hip fracture. Arch Intern Med (2002) 4.20
Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci U S A (1992) 3.61
Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci U S A (1993) 3.29
Renal function and risk of hip and vertebral fractures in older women. Arch Intern Med (2007) 3.27
Minor and major depression and the risk of death in older persons. Arch Gen Psychiatry (1999) 3.15
Interleukin-6 and risk of cognitive decline: MacArthur studies of successful aging. Neurology (2002) 2.68
Serum 25-hydroxyvitamin D concentrations and risk for hip fractures. Ann Intern Med (2008) 2.44
Biomarkers of inflammation and progression of chronic kidney disease. Kidney Int (2005) 2.43
Validity of free testosterone and free estradiol determinations in serum samples from postmenopausal women by theoretical calculations. Cancer Epidemiol Biomarkers Prev (2002) 2.42
Inflammatory markers and incident mobility limitation in the elderly. J Am Geriatr Soc (2004) 2.29
The role of the immune system in the pathophysiology of osteoporosis. Immunol Rev (2005) 2.03
Human soluble IL-6 receptor: its detection and enhanced release by HIV infection. J Immunol (1992) 1.99
Association of kidney function with incident hip fracture in older adults. J Am Soc Nephrol (2006) 1.92
Inflammatory and prothrombotic markers and the progression of renal disease in elderly individuals. J Am Soc Nephrol (2004) 1.91
Inflammation, autotoxicity and Alzheimer disease. Neurobiol Aging (2001) 1.89
Aromatase and breast cancer susceptibility. Endocr Relat Cancer (1999) 1.89
Osteoporosis in men. Endocr Rev (2008) 1.80
Inflammatory markers and incident fracture risk in older men and women: the Health Aging and Body Composition Study. J Bone Miner Res (2007) 1.79
Kidney function and markers of inflammation in elderly persons without chronic kidney disease: the health, aging, and body composition study. Kidney Int (2006) 1.78
Simultaneous block of interleukin-1 and tumor necrosis factor is required to completely prevent bone loss in the early postovariectomy period. Endocrinology (1995) 1.75
Estrogen deficiency induces bone loss by increasing T cell proliferation and lifespan through IFN-gamma-induced class II transactivator. Proc Natl Acad Sci U S A (2003) 1.75
Inflammatory markers and cardiovascular health in older adults. Cardiovasc Res (2005) 1.71
Circulating levels of inflammatory markers predict change in bone mineral density and resorption in older adults: a longitudinal study. J Clin Endocrinol Metab (2008) 1.66
Inflammation, hemostasis, and the risk of kidney function decline in the Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis (2008) 1.56
A positive or a negative confounding variable? A simple teaching aid for clinicians and students. Ann Epidemiol (2005) 1.53
Tumor necrosis factor induces glomerular damage in the rabbit. Am J Pathol (1989) 1.51
T cell activation induces human osteoclast formation via receptor activator of nuclear factor kappaB ligand-dependent and -independent mechanisms. J Bone Miner Res (2001) 1.43
Serum interleukin 6 is a major predictor of bone loss in women specific to the first decade past menopause. J Clin Endocrinol Metab (2001) 1.42
Variation in serum levels of the soluble TNF receptors among healthy individuals. Lymphokine Cytokine Res (1992) 1.33
A randomized comparison of nonoral estradiol delivery in postmenopausal women. Am J Obstet Gynecol (1988) 1.28
A prospective study on socioeconomic aspects of fracture of the proximal femur. J Bone Miner Res (1996) 1.27
Cystatin-C, renal function, and incidence of hip fracture in postmenopausal women. J Am Geriatr Soc (2008) 1.24
Cytokines, bone remodeling, and estrogen deficiency: a 1998 update. Bone (1998) 1.21
Serum testosterone concentrations in women throughout the menstrual cycle and following HCG administration. Am J Obstet Gynecol (1974) 1.16
Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption. Curr Pharm Des (2001) 1.16
Tumors producing human tumor necrosis factor induced hypercalcemia and osteoclastic bone resorption in nude mice. Endocrinology (1989) 1.09
Estrogen deficiency, T cells and bone loss. Cell Immunol (2007) 1.09
Prevention of crescentic glomerulonephritis induced by anti-glomerular membrane antibody in tumor necrosis factor-deficient mice. Lab Invest (1998) 1.03
Contribution of serum inflammatory markers to changes in bone mineral content and density in postmenopausal women: a 1-year investigation. J Clin Densitom (2010) 0.92
Endogenous sex hormones and C-reactive protein in healthy postmenopausal women. J Intern Med (2008) 0.91
Cytokines and bone loss in a 5-year longitudinal study--hormone replacement therapy suppresses serum soluble interleukin-6 receptor and increases interleukin-1-receptor antagonist: the Danish Osteoporosis Prevention Study. J Bone Miner Res (2000) 0.91
SHBG, sex hormones, and inflammatory markers in older women. J Clin Endocrinol Metab (2011) 0.88
Clinical experience with the amniotic fluid lecithin-sphingomyelin ratio. II. The L-S ratio in "stressed pregnancies". Am J Obstet Gynecol (1974) 0.80
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA (2004) 23.69
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med (2007) 18.27
Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA (2006) 12.47
Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 12.44
Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med (2006) 12.09
Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA (2007) 10.50
Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet (2010) 8.89
Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med (2006) 8.73
Estrogen therapy and coronary-artery calcification. N Engl J Med (2007) 8.70
Association of urinary bisphenol A concentration with medical disorders and laboratory abnormalities in adults. JAMA (2008) 8.44
Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med (2011) 8.19
Walking compared with vigorous exercise for the prevention of cardiovascular events in women. N Engl J Med (2002) 7.77
Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA (2010) 7.12
Understanding cancer treatment and outcomes: the Cancer Care Outcomes Research and Surveillance Consortium. J Clin Oncol (2004) 7.02
A pooled analysis of vitamin D dose requirements for fracture prevention. N Engl J Med (2012) 6.85
Frailty: emergence and consequences in women aged 65 and older in the Women's Health Initiative Observational Study. J Am Geriatr Soc (2005) 6.73
Effects of Testosterone Treatment in Older Men. N Engl J Med (2016) 6.66
Prognostic value of usual gait speed in well-functioning older people--results from the Health, Aging and Body Composition Study. J Am Geriatr Soc (2005) 6.54
Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 6.51
Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med (2010) 6.47
Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med (2012) 6.46
Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: a randomized trial. Ann Intern Med (2006) 6.22
Bone-density testing interval and transition to osteoporosis in older women. N Engl J Med (2012) 5.81
Performance of common genetic variants in breast-cancer risk models. N Engl J Med (2010) 5.79
Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med (2004) 5.65
Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med (2010) 5.60
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet (2012) 5.48
Effects of estrogen with and without progestin on urinary incontinence. JAMA (2005) 5.41
Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (2003) 5.38
Prevalence of cognitive impairment without dementia in the United States. Ann Intern Med (2008) 5.34
Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet (2009) 5.22
Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA (2010) 5.20
Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet (2009) 5.14
Comparison of 2 frailty indexes for prediction of falls, disability, fractures, and death in older women. Arch Intern Med (2008) 5.14
High-trauma fractures and low bone mineral density in older women and men. JAMA (2007) 5.00
A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet (2010) 4.89
Effects of estrogen plus progestin on health-related quality of life. N Engl J Med (2003) 4.83
BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures. J Bone Miner Res (2003) 4.64
Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am J Epidemiol (2005) 4.55
Exercise plus behavioral management in patients with Alzheimer disease: a randomized controlled trial. JAMA (2003) 4.54
The Aging, Demographics, and Memory Study: study design and methods. Neuroepidemiology (2005) 4.44
Daily activity energy expenditure and mortality among older adults. JAMA (2006) 4.36
The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res (2012) 4.15
Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst (2004) 4.09
Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA (2003) 4.07
Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease. N Engl J Med (2016) 3.88
Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA (2011) 3.85
Therapy modifications in response to poorly controlled hypertension, dyslipidemia, and diabetes mellitus. Ann Intern Med (2006) 3.71
American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol (2003) 3.71
Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst (2008) 3.60
Subclinical hypothyroidism and the risk of heart failure, other cardiovascular events, and death. Arch Intern Med (2005) 3.56
Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol (2012) 3.56
Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. Arch Intern Med (2010) 3.53
Diabetes, metformin, and breast cancer in postmenopausal women. J Clin Oncol (2012) 3.47
Longitudinal study of muscle strength, quality, and adipose tissue infiltration. Am J Clin Nutr (2009) 3.44
Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association. Circulation (2012) 3.39
Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the health, aging, and body composition study. Arch Intern Med (2005) 3.39
A comparison of prediction models for fractures in older women: is more better? Arch Intern Med (2009) 3.37
Validity of self-report for fractures among a multiethnic cohort of postmenopausal women: results from the Women's Health Initiative observational study and clinical trials. Menopause (2004) 3.33
Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol (2009) 3.33
Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet (2013) 3.31
Renal function and risk of hip and vertebral fractures in older women. Arch Intern Med (2007) 3.27
Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet (2012) 3.21
Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev (2005) 3.20
Meta-analysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality. Ann Intern Med (2008) 3.20
Duration of lactation and risk factors for maternal cardiovascular disease. Obstet Gynecol (2009) 3.18
Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol (2010) 3.17